1. Inicio
  2. Publicaciones
  3. Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in real-world patients: the REQXAA study.

Prospective observational registry of perioperative and periprocedural management of antithrombotic therapy in real-world patients: the REQXAA study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Vivas, David
  • Anguita-Gamez, Maria
  • Esteve-Pastor, Maria Asuncion
  • Echeverri, Marysol
  • Igualada, Jesus
  • Anguita, Manuel
  • Egocheaga, Isabel
  • Nozal-Mateo, Beatriz
  • Abad-Motos, Ane
  • Figuero, Elena
  • Bouzo-Molina, Nuria
  • Lozano, Teresa
  • Alvarez-Ortega, Carlos
  • Torres, Javier
  • Descalzo, Maria Jose
  • Catala, Juan Carlos
  • Martin-Rioboo, Enrique
  • Molines, Alejandra
  • Rodriguez-Contreras, Rocio
  • Carnero-Alcazar, Manuel
  • REQXAA study investigators

Grupos

Abstract

Introduction and objectives There is scarce real-world evidence on the management of perioperative antithrombotic treatment according to current recommendations. The aim of this study was to analyze the management of antithrombotic treatment in patients undergoing surgery or another invasive intervention and to assess the consequences of this management on the occurrence thrombotic or bleeding events. Methods This prospective, observational, multicenter and multispecialty study analyzed patients receiving antithrombotic therapy who underwent surgery or another invasive intervention. The primary endpoint was defined as the incidence of adverse (thrombotic and/or hemorrhagic) events after 30 days of follow-up with respect to management of perioperative antithrombotic drugs. Results We included 1266 patients (male: 63.5%; mean age 72.6 years). Nearly half of the patients (48.6%) were under chronic anticoagulation therapy (mainly for atrial fibrillation; CHA2DS2-VASC: 3.7), while 53.3% of the patients were under chronic antiplatelet therapy (mainly for coronary artery disease). Low ischemic and hemorrhagic risk was found in 66.7% and 51.9%, respectively. Antithrombotic therapy management was in line with current recommendations in only 57.3% of the patients. Inappropriate management of antithrombotic therapy was an independent risk factor for both thrombotic and hemorrhagic events. Conclusions The implementation of recommendations on the perioperative/periprocedural management of antithrombotic therapy in real-world patients is poor. Inappropriate management of antithrombotic treatment is associated with an increase in both thrombotic and hemorrhagic events. Full English text available from: www.revespcardiol.org/en.

Copyright © 2023 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
1885-5857, 1885-5857

REVISTA ESPANOLA DE CARDIOLOGIA  Elsevier Doyma

Tipo:
Article
Páginas:
729-738
Factor de Impacto:
0,385 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 1

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Antiagregación plaquetaria; Anticoagulant; Anticoagulante; Antiplatelet; Antithrombotic; Antitrombóticos; Cirugía; Surgery

Proyectos asociados

ENSAYO DE FASE III, ALEATORIZADO, DOBLE CIEGO, MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE OCTAPLEX, UN CONCENTRADO DE COMPLEJO DE PROTROMBINA DE CUATRO FACTORES (CCP-4F), EN COMPARACIÓN CON EL CCP-4F BERIPLEX® P/N (KCENTRA), PARA LA REVERSIÓ N DE LA ANTICOAGULACIÓN INDUCIDA POR ANTAGONISTAS DE LA VITAMINA K EN PACIENTES QUE REQUIEREN UNA INTERVENCIÓN QUIRÚRGICA DE URGENCIA Y QUE TIENEN UN RIESGO SIGNIFICATIVO DE HEMORRAGIA.

Investigador Principal: MARÍA AZUCENA PAJARES MONCHO

LEX-209 . 2017

FLUID DAY.

Investigador Principal: SALOMÉ MATOSES JAÉN

SED-HEA-2018-01 . 2019

ESTUDIO OBSERVACIONAL PROSPECTIVO ACERCA DEL MANEJO PERIOPERATORIO / PERIPROCEDIMIENTO DE LOS FÁRMACOS ANTITROMBÓTICOS EN EL “MUNDO REAL”: REGISTRO REQXAA.

Investigador Principal: RAQUEL FERRANDIS COMES

SEC-API-2019-01 . 2021

BIOMARKER- GUIDED INTERVENTION TO PREVENT ACUTE KIDNEY INJURY AFTER MAJOR NON-CARDIAC SURGERY THE PROSPECTIVE MULTICENTER RANDOMIZED CONTROLLED INTERVENTIONAL TRIAL. ACRONYM BIGPAK-2.

Investigador Principal: MARÍA ÁNGELES FERRE COLOMER

07-AnIt-20 . 2023

Descripción y evaluación del incremento de los niveles de fibrinógeno mediante test viscoelástico tras el empleo de concentrado de fibrinógeno.

Investigador Principal: MARÍA CATALÁN FERNÁNDEZ

INFIBRI-01-MCF-21 . 2021

Estudio de la coagulopatía adquirida del paciente quemado: Relación con la superficie corporal quemada y el tratamiento aplicado.

Investigador Principal: RAQUEL FERRANDIS COMES

TROMBURNT . PROPIO GRUPO . 2023

Cita

Compartir